EZH2 and lymphoma: The EZH2 inhibitor Valemetostat [44] had an objective response rate (ORR) of 48% in a phase 2 clinical trial (NCT04102150) in the treatment of patients with relapsed or refractory (R/R) adult T-cell leukaemia/lymphoma (ALT).